ANN ARBOR, Mich., Nov. 4, 2019 /PRNewswire/ -- C3 Industries (C3), a premium cannabis producer and retailer headquartered in Ann Arbor, announced today it has closed a round of private financing, bringing the total amount of capital raised to date to over $25 million.  C3 will use the funding to continue

MOUNTAIN GROVE, Mo., Nov. 4, 2019 /PRNewswire/ -- What does a small-town doctor know about health care that's valuable to his colleagues around the world? Plenty, as they face many of the same issues Mercy's Dr. David Barbe (pronounced Barb) has tackled during his 36 years of practice in Mountain Grove, Miss

PALM BEACH GARDENS, Fla., Nov. 4, 2019 /PRNewswire/ -- Seoul National University Bundang Hospital (SNUBH) (https://www.snubh.org/dh/en/

COLUMBUS, Ohio and MORRISVILLE, N.C., Nov. 4, 2019 /PRNewswire/ -- Ernie Green Industries and Gilero announced today that they have made the strategic decision to end their equity partnership, known as EG-GILERO, allowing each company to refocus on their respective core offerings. Going forward, Gilero and Ernie Green Industries will oper

TUCSON, Ariz., Nov. 4, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced that Roland Diggelmann has been appointed to its Board of Directors.

HOUSTON, Nov. 4, 2019 /PRNewswire/ -- Millar, Inc., medical device manufacturer and OEM solutions provider, is pleased to announce an achievement of 50 years serving the life sciences, c

NEW HAVEN, Conn., Nov. 4, 2019 /PRNewswire/ -- Kleo Pharmaceuticals, Inc., a unique immuno-oncology company developing next-generation synthetic bispecific compounds design

VANCOUVER, Nov. 4, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, will report fina

IRVINE, Calif., Nov. 4, 2019 /PRNewswire/ -- Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the appointment of Kenneth Chahine, Ph.D., J.D., as Chief Executive Officer and board member. He will succeed Founder

REDWOOD CITY, Calif., Nov. 4, 2019 /PRNewswire/ -- Revolution Medicines, Inc., a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, today announced an agreement with Amgen to evaluate the combination of RMC-4630, the company's investigational SHP2